

April 25, 2025

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: ir@ppmx.com

Announcement of Sales Launch of New Antibodies/Reagents

Perseus Proteomics Inc. is pleased to announce the sales launch of new antibodies/reagents below:

- Anti-GPR87 antibody (utilized for disease research)
- Anti-Exatecan antibody (utilized for ADC research)

GPR87 is not only being studied as a marker molecule to identify cancer but also as a target molecule for cancer treatment. We have reported the promising results of basic studies on anti-GPR87 antibody as a therapeutic drug through collaborative research with a university in an international scientific journal*. We provide this antibody product as a research-use antibody reagent.

Antibody Drug Conjugates (ADCs) are complex drugs that combine two key features: an agent that kills cancer cells and an antibody that delivers this agent to the cancer cells. ADCs have been garnering attention as next-generation cancer treatments. Anti-Exatecan antibody is sold as a research-use antibody reagent for such ADC studies.

We will continue to support various research activities through products developed using antibody technology accumulated in our drug discovery business.

*: eBioMedicine 2021 May;67:103372

END